Global Anticancer Drugs Market Is Set To Expand At A CAGR Of 6.8% By 2032

The global anticancer drugs market is set to enjoy a valuation of US$ 172.8 Billion in 2022 and further expand at a CAGR of 6.8% to reach US$ 335 Billion by the end of 2032. From 2017-2021 a CAGR of 6.1% was registered for the anticancer drugs market. The global sales of the anticancer drugs market in 2021 were held at US$ 160.9 Billion.

Anticancer drugs account for more than half of global spending on cancer treatment. With more emphasis on drugs, the share of anticancer drug treatment is likely to increase in collective spending on cancer treatment. Anticancer drugs are also known as antineoplastic drug which is effective in the treatment of malignant, or cancerous, disease. There are several major classes of anticancer drugs; these include alkylating agents, antimetabolites, natural products, and hormones

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.factmr.com/connectus/sample?flag=S&rep_id=4350?pj

The all-inclusive Anticancer Drugs market report is a complete study of the market briefing on the market status in the forecast period of 2022-2032. This analysis gives an examination of various segments that are relied upon to witness the quickest development amid the estimated forecast frames and important industry trends, market size, and market share appraisals mentioned in the later part of this report. Anticancer Drugs market study also analyses the market status, growth rate, future trends, market drivers, opportunities and challenges, risks, and entry barriers in relation to the concerned market.

𝐊𝐞𝐲 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐏𝐫𝐨𝐟𝐢𝐥𝐞𝐝

• Hoffmann-La Roche Ltd
• Eli Lilly and Company
• Novartis AG
• Pfizer Inc
• Bayer AG
• AstraZeneca
• Takeda Pharmaceutical Company Limited
• Merck & Co., Inc.
• CELGENE CORPORATION
• Amgen Inc.

𝐒𝐚𝐦𝐩𝐥𝐞 𝐢𝐧𝐜𝐥𝐮𝐝𝐞𝐬:

1. A brief introduction to the research report.
2. Graphical introduction of the regional analysis.
3. Top players in the market with their revenue analysis.
4. Selected illustrations of market insights and trends.
5. Example pages from the report.

𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭:

From a geographic segmentation perspective, the report focuses on the regions that have a material and significant effect on the overall market value. The broad level coverage of the report includes the regions and key countries within the regions of Global, North America, Europe, APAC, MEA

𝐆𝐞𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬:https://www.factmr.com/connectus/sample?flag=RC&rep_id=4350?PJ

Over the past five years (2017-2021), the global market for anticancer medications grew at a CAGR of 7.8%. The third leading cause of death worldwide, behind cardiovascular, parasitic, and infectious disorders, is cancer. In 2021, there were 17.0 million new cancer diagnoses and 9.5 million cancer deaths worldwide, according to Fact.MR data.

By 2040, it is predicted that there will be 16.3 million cancer-related deaths and 27.5 million new cases worldwide due only to population growth and ageing. Due to their effectiveness in treating malignant or cancerous disorders, anticancer medicines have thus demonstrated positive expanding traction over time.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐀𝐧𝐭𝐢𝐜𝐚𝐧𝐜𝐞𝐫 𝐃𝐫𝐮𝐠𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

• By Drug Class :

• Cytotoxic
• Hormonal Therapy
• Targeted Therapy
• Monoclonal antibodies
• Small molecule inhibitors

• By Cancer Type :

• Prostate Cancer
• Lung Cancer
• Breast Cancer
• Melanoma
• Others

• By Distribution Channel :

• Hospital Pharmacies
• Retail Pharmacies

• By Region :

• North America
• Latin America
• Europe
• East Asia
• South Asia & ASEAN
• Oceania
• Middle East & Africa

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞

Prominent anticancer drugs manufacturers are Hoffmann-La Roche Ltd, AbbVie, Eli Lilly and Company, Novartis AG, Pfizer Inc., Bayer AG, AstraZeneca, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Celgene Corporation, Amgen Inc.

The two main strategies used by the major players in the anti-cancer medicine business are the introduction of new products and acquisitions. A significant amount of market enthusiasm is being fueled by player collaboration on research and development as well as the FDA's fast-track approval for life-saving conditions.

• In December 2020, to find and create innovative treatments using E3 degraders against difficult-to-drug targets, AbbVie and Frontier Medicines, Crop. have formed cooperation.

• In January 2021, Bayer expanded its pipeline of prostate cancer treatments by entering into a pharmaceutical purchase agreement with Noria Therapeutics and PSMA Therapeutics.

• In October 2022 - Tavros Therapeutics and Vividion Therapeutics announced a strategic collaboration to discover and enhance targeted oncology programs

• In August 2022 - Bristol Myers Squibb announced that it has successfully completed its acquisition of Turning Point Therapeutics, Inc.

𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨:https://www.factmr.com/report/4350/anticancer-drugs-market

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E Mail : sales@factmr.com

Fact.MR is a market research and consulting firm with deep expertise in emerging market intelligence. Ranging from Automotive and Industry 4.0 to Healthcare, Technology, Chemicals, Materials and even the most niche categories.

This release was published on openPR.